Cetuximab in hemodialysis: A case report

Head and Neck

Volumn 31, Issue 12, 2009, Pages 1647-1650

  Aldoss, Ibrahim T ^a   Plumb, Troy ^b   Zhen, Weining ^b   Lydiatt, Daniel D ^b   Ganti, Apar Kishor ^b,c  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

Author keywords

Cetuximab; Chemoradiation; Head and neck cancer; Hemodialysis; Renal failure

Indexed keywords

CETUXIMAB; CISPLATIN; FLUCONAZOLE;

ACNE; AGED; ANAMNESIS; ARTICLE; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; EDEMA; HEMODIALYSIS; HUMAN; HYPOPHARYNX CARCINOMA; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; LYMPH NODE METASTASIS; MALE; MUCOSA INFLAMMATION; MYCOSIS; PERIORAL EDEMA; PRIORITY JOURNAL; RADIATION DOSE; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; HYPOPHARYNGEAL NEOPLASMS; KIDNEY FAILURE, CHRONIC; MALE; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; RENAL DIALYSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 72449121397     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21057     Document Type: Article

References (18)

1. Soo KC, Tan EH,Wee J, et al. Surgery and adjuvant radiotherapy vs. concurrent chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer: a randomised comparison. Br J Cancer 2005;93:279-286.
2. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European organization for research and treatment of cancer phase III trial. J Natl Cancer Inst 1996;88:890-899. (Pubitemid 26230640)
3. Adelstein D, Li Y, Wagner H, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-98.
4. Brizel D, Albers M, Fisher S, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998;338:1798-1804. (Pubitemid 28277960)
5. Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concurrent lowdose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000;18:1458-1464. (Pubitemid 30205391)
6. Wendt T, Grabenbauer G, Rodel C, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998;16:1318-1324. (Pubitemid 28175746)
7. Forastiere A, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-2098. (Pubitemid 37464533)
8. Bonner J, Harari P, Giralt J, et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578. (Pubitemid 43209104)
9. Cisplatin. Cancer Care Ontario, 2006/2007. http://www. cancercare.on.ca/pdfdrugs/CISPLATI.pdf.
10. Zahra M, Taylor A, Mould G, et al. Concurrent weekly cisplatin chemotherapy and radiotherapy in a haemodialysis patient with locally advanced cervix cancer. Clin Oncol (R Coll Radiol) 2008;20:6-11.
11. Watanabe R, Takiguachi Y, Moriya T, et al. Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer. Br J Cancer 2003;88:25-30. (Pubitemid 36241213)
12. Tomita M, Kurata H, Aoki Y, et al. Pharmacokinetics of paclitaxel and cisplatin in a hemodialysis patient with recurrent ovarian cancer. Anticancer Drugs 2001;12: 485-487. (Pubitemid 32643093)
13. Medical News Today. Cancer/Oncology News. FDA approves ERBITUX(R) (Cetuximab) for treatment of head and neck cancer, March 2006.
14. NCCN. Clinical practice guidelines in oncology. Head and neck cancers, Version 1. PA: National Comprehensive Cancer Network; 2007.
15. Cetuximab. Cancer Care Ontario, July 2007. http://www. cancercare.on.ca/pdfdrugs/Cetuximab.pdf.
16. Product Information: Erbitux™, Cetuximab. NJ: Imclone System Inc. and Bristol Myers Squibb Company; 2007.
17. Jillella AP, Dainer PM, Kallab AM, Ustun C. Treatment of a patient with end-stage renal disease with rituximab: pharmacokinetic evaluation suggests rituximab is not eliminated by hemodialysis. Am J Hematol 2002;71:219-222. (Pubitemid 35253340)
18. Budach W, Bölke E, Homey B. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med 2007;357:514-515. (Pubitemid 47204904)